A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Principal Investigator
Mark Buyyounouski, MD MS
Status
Complete
Date Opened To Accrual
July 28 2017
Date Closed to Accrual
July 09 2018
Disease Site
Genitourinary [GU]
Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
The primary objective is to demonstrate that hypofractionated post-prostatectomy radiotherapy (HYPORT) does not increase patient-reported GI and GU symptoms over conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point.
Patient Population
Patient Population
Patients with adenocarcinoma of the prostate treated primarily with radical prostatectomy; pathologic T-classification pT2 or pT3; pathologic N-classification pN0 or pNX; and no clinical evidence of regional lymph node metastasis.
Target Accrual
282
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.